Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | FDFT1 | P37268 | 6/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8625395 | 0.97 | POLB (0.44) | POLBFDFT1MEN1KMT2AGAA | |
| SCHEMBL8618653 | 0.95 | FDFT1 (0.44) | POLBFDFT1MEN1KMT2AGAA | |
| SCHEMBL8619955 | 0.92 | FDFT1 (0.53) | POLBFDFT1 | |
| SCHEMBL8625401 | 0.91 | POLB (0.45) | POLBFDFT1MEN1KMT2AGAA | |
| SCHEMBL8624038 | 0.90 | FDFT1 (0.57) | POLBFDFT1 | |
| SCHEMBL8623396 | 0.89 | FFAR1 (0.45) | FDFT1MEN1KMT2A | |
| SCHEMBL8622840 | 0.87 | FDFT1 (0.48) | FDFT1 | |
| SCHEMBL8624255 | 0.87 | FDFT1 (0.60) | FDFT1 | |
| SCHEMBL8620506 | 0.86 | S1PR1 (0.50) | FDFT1KDM4EALDH1A1LMNA | |
| SCHEMBL8619754 | 0.85 | FDFT1 (0.50) | FDFT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5712396-A | PHOSPHONOSULFONATE COMPOUNDS USED FOR INHIBITING CHOLESTEROL BIOSYNTHESIS AND ATHEROSCLEROSIS | MAGNIN DAVID R (US) | 1998-01-27 | — | — | US | disclosed |
| US-5567841-A | ANTICHOLESTEROL AGENT | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-10-22 | — | — | US | disclosed |
| US-5470845-A | Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-11-28 | — | — | US | disclosed |
| EP-0595635-A1 | Alpha-phosphorous substituted sulfonate derivatives as squalene synthetase inhibitors | E.R. Squibb & Sons, Inc. (US) | 1994-05-04 | — | — | EP | disclosed |